Embryonic stem cells hold great promise for various diseases because of their unlimited capacity for self-renewal and ability to differentiate into any cell type in the body. However, despite over 3 decades of research, there have been no reports on the safety and potential efficacy of pluripotent stem cell progeny in Asian patients with any disease. Here, we report the safety and tolerability of subretinal transplantation of human embryonic-stem-cell (hESC)-derived retinal pigment epithelium in four Asian patients: two with dry age-related macular degeneration and two with Stargardt macular dystrophy. They were followed for 1 year. There was no evidence of adverse proliferation, tumorigenicity, ectopic tissue formation, or other serious safety issues related to the transplanted cells. Visual acuity improved 9-19 letters in three patients and remained stable (+1 letter) in one patient. The results confirmed that hESC-derived cells could serve as a potentially safe new source for regenerative medicine.
INTRODUCTION
Since their discovery and isolation in 1998, human embryonic stem cells (hESCs) have been considered a potentially valuable tool for generating replacement cells for therapeutic purposes ). However, despite success in numerous animal models, fears over tumorigenicity and immunogenicity, coupled with ethical concerns, and inefficiencies in differentiation methods have all contributed to delays in carrying out human clinical trials. Only one group has reported the results of the safety and possible biological activity of embryonic stem cell progeny in individuals with any disease (Schwartz et al., 2015) , but these investigators only enrolled patients who were mostly Caucasian. Here, we confirmed the potential safety and efficacy of hESC-derived cells in Asian patients.
Loss of the retinal pigment epithelium (RPE) is an important part of the disease process in several retinal disorders, including age-related macular degeneration (AMD) and Stargardt disease. AMD is a degenerative disease that is the leading cause of visual impairment in developed countries, with the dry (nonexudative) form of AMD accounting for 85% to 90% of cases (Age-Related Eye Disease Study Research Group, 2001) . Concurrent RPE and choriocapillaris atrophy are present in severe, atrophic dry AMD, with RPE atrophy preceding choriocapillaris atrophy (Schatz and McDonald, 1989; Korte et al., 1984; Leonard et al., 1997) . Stargardt macular dystrophy (SMD) is the most common form of juvenile macular degeneration that is due to the production of defective rim proteins encoded by the ABCA4 gene, leading to the accumulation of di-retinoidpyridinium ethanolamine (A2E) in the RPE, RPE cell loss, and photoreceptor death (Glazer and Dryja, 2002) . There are no known effective treatments to prevent or reverse visual loss for either disease. Since RPE loss is implicated in the pathophysiology of both disorders, RPE replacement has been suggested as a therapeutic intervention for these conditions.
Proper functioning of the RPE is important for maintaining the health and integrity of the outer retina, photoreceptors, and choriocapillaris. Healthy RPE cells play many crucial roles in the retina, including transportation of nutrients such as glucose or vitamin A from blood to the photoreceptors, secretion of growth factors, phagocytosis of the outer segments of the photoreceptors, formation of the blood-retina barrier by tight junctions, and establishment of immune privilege of the eye (Strauss, 2005; Wimmers et al., 2007) . Based on the central role of RPE in the pathophysiology of AMD, researchers have attempted allogeneic and autologous RPE cell transplantations for cases of wet AMD (Binder et al., 2002; van Meurs et al., 2004; Algvere et al., 1994) and dry AMD (Algvere et al., 1997 (Algvere et al., , 1999 Joussen et al., 2007) . However, most of these clinical trials have failed to show functional improvements in macular degeneration patients, possibly because of immune rejection and graft failure.
Animal studies have shown that hESC-derived RPE cell transplantation can rescue photoreceptors, resulting in the improvement of visual functions in RPE-oriented retinal degeneration models (Lund et al., 2006; Lu et al., 2009) . Clinical trials of hESC-derived RPE cell transplantation have begun recently in the United States and Europe, and Schwartz et al. have reported preliminary safety data on one dry AMD patient and one SMD patient (Schwartz et al., 2012) , as well as follow-up data with nine dry AMD and nine SMD patients (Schwartz et al., 2015) . The patient population studied in this paper was all Caucasian, except for one African American patient with SMD. Our report provides interim results of the first pluripotent stem cell trials performed in Asian patients, who may carry different risk alleles for the development of some retinal disorders such as AMD. For example, the Y402H and R80G (in the C3 gene) variants have been associated with AMD in Caucasians but not in Asians (Chen et al., 2006; Mori et al., 2007; Kim et al., 2008; Ng et al., 2008; Lee et al., 2008; Kondo et al., 2009; Goto et al., 2009; Pei et al., 2009) . Herein, we report on four Asian patients with macular degeneration (two with AMD and two with SMD) who underwent subretinal transplantation of hESC-derived RPE and were followed for 1 year to assess safety and tolerability.
RESULTS

Derivation of RPE Cells from hESCs
The hESC-derived RPE displayed typical RPE behavior, such as pigmentation during differentiation and maturation, and also exhibited a cuboidal epithelial morphology in tissue culture. During culture, we observed clusters of pigmented RPE cell monolayers that exhibited their unique cobblestone morphology at the edges of clusters ( Figures  1A and 1B) . Karyotype results using g-banding showed 46XX, a normal female karyotype ( Figure 1C ). Thawed cells were cultured for 2-3 weeks until fully differentiated to human RPE (hRPE) cells with medium pigmentation (Figure 1D ) and were stained for hRPE markers, including ZO1, PAX-6, MITF, and Bestrophin ( Figures 1E-1I ). We observed that >99% of cells expressed hRPE markers. For cell function analysis, we used phagocytosis assay kits using fluorescence-labeled bioparticles. Visual imaging of the differentiated hESC-derived RPE cells with fluorescence microscopy showed that most hRPE cells could phagocytize the fluorescently labeled beads (Figures 1J-1L) . As for the quantification of the potency assay, fluorescence-activated cell sorting (FACS) analysis was conducted with hESCderived RPE cells immediately post-thawing, which is more relevant to the phenotype of the cells that are actually transplanted ( Figure S1 ). The percentage of cells phagocytized with fluorescence-labeled bioparticles was measured compared to a negative isotype control and an untreated negative control (test group at 37 C: 98.47% ± 0.32%, n = 3; isotype contol at 4 C: 34.47% ± 3.67%, n = 3; untreated negative control at 37 C: 5.52% ± 0.72%, n = 3) ( Figure S1 ). 16-STR (short tandem repeat) genetic analysis using amplified genomic DNA (gDNA) proved that RPE cells originated from MA09. Immunostaining of OCT-4 and NANOG was conducted for impurity testing to confirm that no hESCs were present ( Figure 1M ). We counted DAPI-stained cells in three different fields and calculated the total cell number, and we did not see any cells that stained positive for OCT-4 + or NANOG + within 21-mm dishes ( Figure 1M ). Additionally, we performed FACS using fluorescent labels for OCT-4 and TRA- 
Clinical Trial Results
The first advanced dry-AMD patient was a 79-year-old male with an initial best-corrected visual acuity (BCVA) of the study eye of one letter read and of the fellow eye of 20/25 (80 letters) on a Bailey-Lovie chart. During surgery, retinal detachment was difficult to initiate at the first retinotomy site, and subretinal cells were injected at a second site. A small subretinal hemorrhage was noted at this second site (Figure 2B) . We estimated that 4 3 10 4 cells were injected subretinally. The hemorrhage absorbed spontaneously at postoperative 26 weeks ( Figure 2C ). Immunosuppression was stopped 4 weeks postoperatively because of repeated elevation of serum creatinine levels, blood urea nitrogen (BUN) levels, and potassium levels, as well as bone marrow suppression and diarrhea; these adverse events returned to preoperative levels after the cessation of immunosuppression. An epiretinal membrane developed at 2 weeks, with dark brown pre-retinal pigmentation from 3 weeks. The epiretinal membrane enlarged until 8 weeks, causing minimal distortion of the underlying inner retina, and the pre-retinal pigmentation area increased and darkened by 13 weeks, with no change through 1 year ( Figure 2D ). Subretinal pigmentation started at 3 weeks as an oval-shaped, localized black clump. The clump was slightly increased in size until 13 weeks as the subretinal hemorrhage decreased. Blocked autofluorescence was noted at these pre-retinal and subretinal pigmentation areas ( Figure 2F ). Choroidal neovascularization (CNV) was present on fluorescein angiography temporal to the area of preoperative geographic atrophy (GA) at postoperative 33 weeks (Figures 2E and 2F) . Leakage on fluorescein angiography improved ( Figure 2G ) after three monthly intravitreal Lucentis (0.5 mg/0.05 ml, Genentech) injections. At the 1-year visit, BCVA was stable in the study eye (two letters read; Table 1 ) without subjective symptoms, and an epiretinal membrane persisted with minimal retinal puckering ( Figure 2H ). There was minimal enlargement of the central scotoma on Goldmann perimetry and no significant change in electroretinography (ERG) and multifocal electroretinography (mfERG) (Figures 2J and 2L; Table 2 ). The BCVA of the fellow eye was 20/32 (75 letters). Coryza, senile purpura, gynecomastia, constipation, and allergic conjunctivitis were adverse events with no causal 20/80 (55 letters) in the fellow eye. During subretinal injection of cells through the first retinotomy at the inferotemporal macula, the bleb encroached upon the fovea. As per the protocol, the injection was stopped, and another retinotomy and subretinal injection of the remaining cells were performed through a distant retinotomy in the superotemporal macula. Intraocular pressure elevation, corneal erosions, and corneal abrasion were adverse events related to the vitrectomy procedure that subsided after the administration of topical eye drops. Subretinal pigmentation was observed starting at postoperative 3 weeks as dark brown to black scattered small oval clumps inside the bleb area, and the number of clumps increased until 6 weeks and did not change through 52 weeks ( Figures 3A and 3B ). After the surgery, stippled hyper-autofluorescence dots were observed at the border of the atrophic zone where the bleb was Hexagons in which the bleb involved at least half of its area were included. For both study eyes and fellow eyes, n = 5; a total of four eyes and five blebs due to two blebs in the second AMD patient. NA, not applicable. a Response density (nanovolts per square degree). b Wilcoxon's signed-rank test of the changes of the study eyes. Wilcoxon's rank-sum test between the changes in the study eyes and those in the fellow eyes. d 3 months(6 months, 12 months)-baseline indicates the change from baseline to the corresponding month after surgery.
involved ( Figures 3C and 3D ). An epiretinal membrane developed at postoperative 2 weeks, with pre-retinal pigmentation starting at 3 weeks, which increased in size until 15 weeks. Minimal puckering of the underlying retina accompanied this pigmented epiretinal membrane. Stippled hypo-autofluorescence at subretinal pigmented areas and patchy hypo-autofluorescence at preretinal pigmentation areas were noted ( Figure 3D ). Retinal cysts were noted at the center of the GA area at 26 weeks on spectral domain optical coherence tomography (SD-OCT 3H ) and mfERG of the injection sites (Table 2) were stable after the surgery. In the fellow eye, BCVA deteriorated to 20/200 (35 letters). Systemic adverse events considered to be unrelated to the study procedures included laryngopharyngeal reflux that developed at 3 weeks and improved at 13 weeks, upper respiratory infection with rhinorrhea at 42 weeks, and potassium level elevation at 52 weeks. These adverse events improved after medical therapy. Diarrhea, indigestion, and tinnitus were mild events not related to the study procedures and subsided spontaneously. The patient experienced intermittent right-hand tremor starting at approximately 15 weeks and received acupuncture several times without informing the investigators. At 26 weeks, a neurologist evaluated the patient and determined this event as age-related changes not related to the study procedure. Pneumonia, which may have been related to immunosuppression, was diagnosed at 8 weeks at our pulmonary department and then subsided after 3 days of oral antibiotics treatment. Our first SMD patient was a 45-year-old male with an initial BCVA of counting fingers (one ETDRS letter). There were no signs of anterior chamber or vitreous cell or flare beyond what would be typically seen in the postoperative period. The patient had corneal erosions in his left eye after the ERG, and he recovered without sequelae with prophylactic topical antibiotic eye drops. No pigmentation or autofluorescence changes were noted after the hESC-RPE transplantation in this patient ( Figures 4A-4D ). At postoperative 52 weeks, his BCVA had gradually improved to 20/640 (13 ETDRS letters; Table 1 ), and a smaller central scotoma was observed via Goldmann visual field examination ( Figures 4E and 4F) . BCVA of the fellow eye was 20/800 (4 ETDRS letters read) before the surgery and 20/500 (13 letters) at 52 weeks. There was no change in the anatomic appearance on SD-OCT and no change in either the ERG ( Figures 4D and 4H ) or mfERG (Table 2) after surgery. Herpetic vesicles developed on the patient's right arm that were possibly related to immunosuppressive mycophenolate mofetil (MMF); these were treated with topical acyclovir application without changes in his immunosuppressive regimen. Skin bullae at the left forearm, a contusion of the right hand, external otitis, rhinorrhea, sneezing, fatigue, headache, upper respiratory infection, and chronic gingivitis were mild adverse events observed that had no causal relationship with the procedure, as determined by the rheumatologist and relevant specialists.
The second SMD patient was a 40-year-old male. His BCVA improved from 20/640 (13 ETDRS letters) to 20/250 (32 letters) at 1 year. BCVA of the fellow eye was 20/250 (32 letters) at baseline and 20/160 (41 letters) at 1 year. Subretinal pigmentation started at 4 weeks in the bleb area, and the number of pigmentations increased in number until 6 weeks, with hypo-autofluorescence that persisted until 52 weeks ( Figures 5A-5D ). Multiple increased autofluorescence spots were also observed inside the bleb area where hESC-RPE was injected ( Figure 5D ). Because of a large initial central scotoma and poor visual function, visual field examinations were unreliable, and there was no obvious change after surgery. ERG and the multifocal ERG of the injection site were stable throughout 52 weeks (Figures 5E and 5F ; Table 2 ). Upper respiratory infection, aggravation of reflux esophagitis, and loss of a dental implant were mild adverse events considered unrelated to the study procedures.
The first SMD patient had three missense mutations: c.983A > T (Glu328Val), c.1933G > A (Asp645Asn), and c.3106G > A (Glu1036Lys). The second SMD patient had two missense mutations: c.2894A > G (Asn965Ser) and c.4972A > C (Ser1658Arg). All of these mutations, except for the c.4972A > C mutation in S-004, were previously reported as Stargardt-associated mutations (Jaakson et al., 2003) .
DISCUSSION
The purpose of this study was to determine the safety and tolerability of the subretinal injection of hESC-derived RPE cells as a treatment for dry AMD and SMD. No serious systemic or ocular adverse events occurred in these four Asian patients. Ophthalmological examinations, including ETDRS visual acuity, visual field examination, color fundus photography, fundus fluorescein angiography, optical coherence tomography, fundus autofluorescence photography, ERG, and mfERG did not identify any significant safety concerns after surgery.
This present study was an open-label trial of patients who had poor visual function preoperatively with a large central scotoma, which hindered our ability to perform reliable measurements of visual functions. In the two dry-AMD patients, visual acuity in the treated eyes improved by one letter (stable at counting fingers at 4 ft) and nine letters (a two-line improvement from 20/320 to 20/200) at 52 weeks, respectively. In contrast, the fellow (untreated) eyes decreased by 6 and 20 letters, respectively, during the same time period. In the two SMD patients, visual acuity improved in the treated eyes by 12 letters (counting fingers at 2 ft to 20/640) and 19 letters (a four-line improvement from 20/640 to 20/250), respectively, compared with nine letters of improvement in the fellow eyes at 52 weeks compared to baseline. The visual acuity improvement noted in the fellow eyes of SMD patients may be due to poorer baseline visual acuity than in the fellow eyes of the dry AMD patients. A 15-letter improvement (a doubling of the visual angle) is generally accepted as a clinically significant change. The sample size in these studies (SMD phase 1: 3 patients; dry AMD phase 1/2a: total of 12 patients, with 3 for each dose) was not powered to detect an improvement in visual acuity. Thus, the visual acuity measurement in these preliminary data should be primarily interpreted as a safety parameter to monitor for adverse effects from the transplants. It is important to note that there was no decline in visual acuity in any of the four eyes.
Humphrey visual field examinations were unreliable because of poor fixation and high false-negatives in nearly all of the participants. Goldmann visual field (GVF) examinations were assessed in these patients. There was no significant change in the visual field and mfERG examinations in these eyes.
In the two dry AMD patients and one SMD patient, increasing subretinal pigmentation developed at the hESC-RPE cell injection site as has been noted previously (Schwartz et al., 2012 (Schwartz et al., , 2015 . In the second dry AMD patient and the second SMD patient, multiple spots of increased autofluorescence were also observed at the injection sites. It is tempting to speculate that the subretinal pigmentation may represent engrafted RPE, and this conclusion is strengthened by the observations of small deposits on the inner aspects of Bruch's membrane after surgery on OCT. However, it is known that pigment is not a robust marker of donor cells, since ingestion of donor pigment by host macrophages may produce a similar ophthalmoscopic appearance. Although there is no host RPE in the regions of atrophy, prior studies have shown that native adult RPE cells may proliferate and migrate within 72 hr after retinal detachment in cats (Anderson et al., 1981) ; migration of host RPE and ingestion of pigment by these cells may also explain the appearance of subretinal pigment after hESC-RPE injection. It is important to note that the subretinal pigmentation and stippled hyperautofluorescence spots noted after subretinal hESC-RPE injection have not been reported in eyes after similar procedures with Ca-and Mg-free solution in other trials where transient retinal detachment was performed in order to achieve subretinal viral vector administration (Maguire et al., 2008) .
One of the largest concerns in the clinical applications of hESC-derived cell therapy is potential tumorigenicity. Teratoma formation is observed within 8 weeks (Klimanskaya et al., 2005) . All of our patients were followed for at least 1 year, and, using color fundus photography, autofluorescence imaging, and SD-OCT with 3-mm resolution, we found no unwanted abnormal proliferation suggesting teratoma formation.
Since the donor hESC-derived cells are allografts, there is the possibility of graft rejection after transplantation. Previous allogeneic RPE cell transplantations in dry AMD resulted in graft rejections in some cases, although it started later in the treatment course and was seen less frequently than in patients with wet AMD (Algvere et al., 1997 (Algvere et al., , 1999 . We did not observe any clinically significant intraocular inflammation and detected no signs of obvious immune rejection including fluid collection, edema, fibrous membrane formation, persistent leakage on fluorescein angiography, or graying or loss of pigmentation of the graft in patients who underwent graft transplantation and were able to maintain systemic immunosuppression. The second dry AMD patient developed intraretinal cysts and dye pooling on fluorescein angiography that did not change for 52 weeks after surgery. No significant changes in visual acuity, multifocal ERG, symptoms, or other signs of intraocular inflammation accompanied this change. The subretinal and pre-retinal pigmentations persisted without change. Cystoid macular edema is present in approximately 20%-40% of patients with epiretinal membrane (Wickham and Gregor, 2013) . The retinal cyst may have accompanied the epiretinal membrane in this patient. However, this does not rule out the possibility of graft rejection.
The moderate adverse events related to immunosuppression included creatinine level elevation in the first dry AMD patient and pneumonia in the second dry AMD patient. Immunosuppressive medication was stopped in the first patient because of repeated deterioration of renal function, including creatinine and potassium level elevation. We could continue the dosage of immunosuppression per protocol in three patients. The dose and mandatory period of immunosuppression should be determined in the future trials.
The two dry AMD patients developed epiretinal membranes with pigmentation. This is relatively high compared with the rate of epiretinal membrane development after the vitrectomy procedure. It may arise from inadvertent preretinal injection of cells or reflux of transplanted cells from the subretinal space. These pre-retinal patches of pigmentation did not contract and cause macular wrinkling enough to require additional surgery during the follow-up interval.
The first dry AMD patient developed CNV in the hESC-RPE transplanted eye at 33 weeks. The location of the CNV was not primarily in the bleb area, and only the superior margin of the CNV adjoined the inferior margin of the previous bleb location. This patient had drusenoid subretinal accumulation with GA in the study eye and drusenoid pigment epithelial detachment (PED) in the fellow eye. A previous report showed a relatively high rate of development of CNV (23%) in eyes with drusenoid PED with no advanced AMD at baseline (Cukras et al., 2010) . The CNV may have developed as a natural course, or it may have been due to trauma to Bruch's membrane during the surgical procedure or from the injected hESC-RPE.
The present report confirmed the feasibility and preliminary safety of hESC-RPE cell therapy. Continued follow-up and further study are needed to determine the long-term safety and efficacy of hESC-derived cells as a potential source of replacement cells for the treatment of macular degeneration.
EXPERIMENTAL PROCEDURES
hESC-derived RPE cells were manufactured in a fully validated good-manufacturing-practice (GMP) facility under strict environmental control monitoring systems and routine microbial testing regimens at CHA Biotech. Master and working cell banks were established using the hESC line MA09 (Ocata Therapeutics, previously Advanced Cell Technology) (Schwartz et al., 2012) , which was registered with the Korea Centers for Disease Control and Prevention as an imported stem cell line. The comparability of MA09-hRPE cells manufactured from both GMP sites (CHA Biotech versus Ocata Therapeutics) was confirmed by characterizing the MA09-hRPE cells in terms of karyotype, genetic analysis, identity, purity, and potency by using real-time PCR, immunocytochemistry, FACS analysis, and phagocytosis assays (Supplemental Information).
The MFDS and CHA Bundang Medical Center institutional review board (IRB) approval was obtained to carry out two prospective clinical trials to evaluate the safety and tolerability of the cells in patients with SMD and dry AMD (registered with ClinicalTrials. gov [https://clinicaltrials.gov]; numbers NCT01625559 and NCT01674829). The protocols are similar to those of the U.S. studies (NCT01345006 and NCT01344993), with some differences regarding cancer screening and immunosuppression (see Supplemental Information). Cancer screening included complete history recording, physical examination, laboratory tests, and further ultrasonography, endoscopy, and biopsy when needed. Immunosuppression was started at lower dosages of tacrolimus and MMF; the doses were gradually titrated according to each patient's serum tacrolimus level (3-7 ng/ml), with tolerability judged by a clinical rheumatologic specialist, while the ophthalmologists monitored the patient for changes in the clinical examinations. Lower MMF dosages of 1.0-1.5 g/day were used according to previous reports regarding its safety and efficacy in the Asian organ transplantation patients (Tsang et al., 2000; Kim et al., 2010) . Both immunosuppressive drugs were started 1 week prior to the surgical procedure and were continued for a period of 7 weeks until postoperative 6 weeks. Next, the tacrolimus was discontinued, and the MMF was continued for an additional 7 weeks before being slowly tapered thereafter. In the case of SMD, ABCA4 genes were examined using the exome sequencing method, with a portion of the blood specimen archived for safety purposes at baseline. Surgeries were carried out at the CHA Bundang Medical Center by a single surgeon (W.K.S.). Posterior pars plana vitrectomy was performed in the eye with the worse vision, with induction of posterior vitreous detachment (PVD). A volume of 150 ml of RPE reconstituted in BSS Plus was injected into the subretinal space via a 38-G subretinal cannula, delivering the target dose of 5 3 10 4 RPE cells. Patients were kept in a supine position for at least 6 hr after the operation. Patients were closely monitored by physical examinations, laboratory examinations, and ophthalmologic examinations, including BCVA analysis using a Bailey-Lovie chart, visual field examination using Goldmann visual field testing (Projection perimeter MK-70ST L-1550, Inami Ophthalmic Instruments) and/or automated testing using a validated Humphrey perimeter (Humphrey Field Analyzer; Carl Zeiss Meditec), fundus photography, fluorescein angiography (KOWA VX-10i; Kowa), SD-OCT, fundus autofluorescence photography (Spectralis OCT; Heidelberg Engineering), and ERG (UTAS E-3000 system; LKC Technologies) (see Tables S1 and S2 for the schedule of assessments). 
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